logo
Frito-Lay Recalls Some Tostitos Tortilla Chips With 'Life-Threatening' Warning

Frito-Lay Recalls Some Tostitos Tortilla Chips With 'Life-Threatening' Warning

Yahoo05-04-2025
Frito-Lay has issued a recall for some of its Tostitos tortilla chips.
"Frito-Lay today issued a recall of a limited number of 13 oz. bags of Tostitos Cantina Traditional Yellow Corn Tortilla Chips that could include nacho cheese tortilla chips, and therefore may contain undeclared milk," the recall notice reads on the website of the U.S. Food and Drug Administration.
"Those with an allergy or severe sensitivity to milk run the risk of a serious or life-threatening allergic reaction if they consume the recalled product," the notice says.
"The product included in this recall was distributed to a mix of retailers including grocery, convenience and drug stores, as well as e-commerce distributors, in the following 13 states: Alabama, Florida, Georgia, Illinois, Indiana, Kentucky, Mississippi, North Carolina, Ohio, South Carolina, Tennessee, Virginia and West Virginia. Consumers would have been able to purchase these chips as early as March 7, 2025," the FDA wrote on its website.
The FDA noted that the recall is as a precaution because no injuries have been reported thus far.
"No allergic reactions related to this matter have been reported to date. No other Tostitos products, flavors, sizes or variety packs are recalled," wrote the FDA. "Less than 1,300 bags are included in the recall."
"If consumers have an allergy or sensitivity to milk, they should not consume the product and discard it immediately. Frito-Lay has informed the FDA of this action," the FDA noted.
A news release from Frito-Lay adds, "Consumers with the product described above can visit the Frito-Lay Contact Us page here or call 1-800-352-4477 (9 a.m. – 4:30 p.m. CST, Monday-Friday." The release contains a chart with more details on the recalled product.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Novo Nordisk Soars After 50% Ozempic Discount, Liver Treatment Approval
Novo Nordisk Soars After 50% Ozempic Discount, Liver Treatment Approval

Yahoo

time38 minutes ago

  • Yahoo

Novo Nordisk Soars After 50% Ozempic Discount, Liver Treatment Approval

Cash truly is king. On Monday, shares in Novo Nordisk jumped 4% after the drugmaker announced that US customers who pay out-of-pocket will be able to buy its blockbuster diabetes drug Ozempic for less than half the list price. In a year of struggles against copycats, an emboldened chief rival and political pressure over high prices, executives are no doubt hoping the discount will prove a crowning achievement. READ ALSO: SoftBank Acquires a 2% Stake in Embattled Intel and Brokers Chafe Under Abrupt Expansion of Steel, Aluminum Tariffs A Letter from Washington Without insurance, Ozempic can set back US customers roughly $1,350 a month, or enough to rent a one-bedroom apartment in Kansas City (where the local barbecue might have you in need of a GLP-1 prescription). That hefty price tag has led to a bipartisan pushback in Washington, including from President Donald Trump, who sent a letter to Novo last month demanding executives lower prices for their company's treatments. Trump also urged drugmakers to develop direct-to-consumer sales models for their medicines. Americans spent $98 billion out of pocket on prescriptions last year, a 25% cumulative increase over five years, according to IQVIA, while a majority worry that prescription costs are unaffordable, according to KFF polling. Meanwhile, Novo has its own incentives to lower prices. For one, customers flocked to cheaper copycat drugs that exploded in popularity during a multi-year GLP-1 shortage, one that the FDA declared over earlier this year. And the company's chief rival in the GLP-1 space, Mounjaro- and Zepbound-maker Eli Lilly, has been binge-eating market share. Last month, the pressure prompted Novo to slash its sales and profit forecasts, prompting a massive selloff on Wall Street (shares are down 37% this year). On Monday, the company signalled it will defend its turf: Novo said cash-paying Americans can now buy Ozempic for $499 per month through its official website, its patient assistance program, its newly launched direct-to-consumer online pharmacy, or through discount telehealth platform GoodRx. The move follows Novo's decision to halve the price of weight-loss treatment Wegovy in March. Its price reductions follow similar cuts from Eli Lilly, which slashed the prices of both its weight loss and obesity GLP-1 drugs in March. David Ricks, Eli Lilly's CEO, said at the time that about 10% of the 1 million people who bought Zepbound did so from the company's website. MASHing Success: Monday's news came on the heels of a Friday victory for Novo, when Wegovy received FDA approval to treat metabolic dysfunction-associated steatohepatitis (MASH), a liver condition that affects roughly 5% of US adults, potentially opening up a market of millions of new customers. It was the first GLP-1 treatment to be approved for MASH, giving Novo a leg up against its biggest competitor. Rival Lilly, meanwhile, has run trials, inked deals and even made an acquisition earlier this year with an eye to rolling out MASH treatments. This post first appeared on The Daily Upside. To receive delivering razor sharp analysis and perspective on all things finance, economics, and markets, subscribe to our free The Daily Upside newsletter.

Life Molecular Imaging Expands Neuraceq® (florbetaben F-18 injection) Production in Southern California
Life Molecular Imaging Expands Neuraceq® (florbetaben F-18 injection) Production in Southern California

Yahoo

timean hour ago

  • Yahoo

Life Molecular Imaging Expands Neuraceq® (florbetaben F-18 injection) Production in Southern California

Unlocking a new geography, making Neuraceq® available to more patients BOSTON, Aug. 20, 2025 /PRNewswire/ -- Life Molecular Imaging (LMI), a Lantheus company, dedicated to developing and offering novel PET radiopharmaceuticals, has expanded its manufacturing and distribution network for Neuraceq® (florbetaben F-18 injection) in Southern California. This expansion increases access to the broader Southern California area, including San Diego, extending availability of Neuraceq® to imaging centers, physicians, and patients with cognitive impairment. The first dose from a newly-equipped site in Los Angeles was provided on August 13, 2025. Neuraceq® is an FDA-approved radioactive diagnostic agent for the detection of amyloid plaques in the brain of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline. Neuraceq® is used in clinical routine and is also a powerful diagnostic tool for the appropriate characterization of patients assessed for treatment eligibility with newly approved anti-amyloid drugs. This expansion reflects LMI's ongoing commitment to advancing diagnostic access and improving outcomes for patients affected by Alzheimer's disease in California. "At LMI, we are focused on expanding geographical access to Neuraceq® for patients and physicians involved in the evaluation of Alzheimer's disease. As the adoption of anti-amyloid therapies continues to grow, the demand for reliable amyloid PET imaging is increasing in parallel. Launching Neuraceq® from Los Angeles is a key milestone in meeting this rising demand. It reflects our ongoing dedication to delivering timely, high-quality diagnostic solutions that align with the evolving needs of neurologists and patients," said Colleen Ruby, US Country Head and Chief Operating Officer, Americas and APAC of LMI, a Lantheus company. About Neuraceq® (florbetaben 18F) Indications and Use NEURACEQ is a radioactive diagnostic drug indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: Evaluation of Alzheimer's disease (AD) and other causes of cognitive decline, and selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products. CONTRAINDICATIONS: None WARNINGS AND PRECAUTIONS: Risk for Image Misinterpretation and other Errors: NEURACEQ Risk of Image Misinterpretation and Other Errors: Image interpretation errors have been observed. [see Section 5.1 of the full prescribing information] Radiation Risk: NEURACEQ, similar to other radiopharmaceuticals, contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to protect patients and health care workers from unintentional radiation exposure [see Dosage and Administration in the full prescribing information]. ADVERSE REACTIONS: The most commonly reported adverse reactions in clinical trials were injection site pain (3.4%), injection/application site erythema (1.7%), and injection site irritation (1.1%). For more information please visit: About Life Molecular Imaging (LMI) Life Molecular Imaging (LMI), a Lantheus company, is dedicated to developing and offering novel cutting-edge PET radiopharmaceuticals for imaging of neurodegenerative and cardiovascular diseases. The organization strives to be a leader in the molecular imaging field. Our mission is to pioneer innovative PET products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life. By advancing novel PET radiopharmaceuticals for molecular imaging, LMI is focusing on a key field of modern medicine. To learn more about LMI, please visit About LantheusLantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Switzerland and Sweden, Lantheus has been providing radiopharmaceutical solutions for nearly 70 years. For more information, visit ContactsInvestor Relations: Mark KinarneyVice President, Investor Relations978-671-8842ir@ Media: Melissa DownsExecutive Director, External Communications646-975-2533media@ View original content to download multimedia: SOURCE Life Molecular Imaging

Americans' faith in food safety plummets
Americans' faith in food safety plummets

Yahoo

time2 hours ago

  • Yahoo

Americans' faith in food safety plummets

Over the past several months, the federal government has made extensive cuts to instrumental food health and safety organizations like the Food and Drug Administration (FDA), the U.S. Department of Agriculture (USDA), and the Center for Disease Control. And now, Gallup polling released this week says American confidence in the government to ensure food safety is at a new low. Shocker. Only 53% of Americans say they have a 'great deal' or 'fair amount' of confidence in food safety. This number has been dropping since 2006, however, there was a sharp decline starting in 2019. Despite this, 84% of Americans still report that their diet is at least 'somewhat healthy,' a number that has stayed consistent since Gallup started this reporting in 2001, but there hasn't been much — if any — increase in how many people are paying attention to nutrition labels and food warnings. Something that has become increasingly necessary as new food recalls are being announced almost daily. The USDA and FDA release public notices when they become aware of a recall, however, some of these notices aren't released until weeks or months after a contamination was reported. These recalls aren't always the easiest to find, sometimes they're hiding in the FDA Enforcement Report, which is completely different from the Recall, Market Withdrawals, & Safety Alerts Data Base. For example, in this week's enforcement report there are six ongoing recalls from the same company (King Cheesecake Company Inc.) because various products included pecans that were potentially contaminated with salmonella. This is listed as a Class I recall, the most serious from the FDA. The recall was initiated on July 18, but not classified by the FDA until August 7. To make matters worse, there is no listed press release for the recall even though it affects products and consumers in six different states including Alabama, Texas, Florida, Louisiana, Oklahoma and Illinois. Despite the cuts, officials have maintained that the number of inspectors and other food regulators will not change. Other experts are saying these cuts are a massive threat to public health and safety and could lead to dangerous disease outbreaks and consistent food recalls. Who's to say which is true, but it's clear the majority of Americans aren't confident in our food systems right now. All in the name of making America healthy again — apparently. The post Americans' faith in food safety plummets appeared first on Solve the daily Crossword

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store